Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.

被引：0
|
作者：
Ravandi, Farhad
Carraway, Hetty E.
Taningco, Lilia
Laille, Eric
Gong, Jing
Prebet, Thomas
De Menezes, Daniel Lopes
Wei, Andrew H.
机构：
[1] Univ Texas MD derson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Taussig Canc Inst, Cleveland Clin, Leukemia Program, Cleveland, OH USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Peter MacCallum Canc Ctr, Melbourne, VIC, Australia
[5] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7068
引用
收藏
页数：1
相关论文
共 50 条
  • [41] UCHMC 1812: A phase 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.
    Gaut, Daria Louise
    Callas, Bradley
    Damon, Lloyd Earl
    Jonas, Brian Andrew
    Jeyakumar, Deepa
    Borror, Catherine
    Osorio, Stephanie
    Ta, Teresa
    Park, Sunmin
    Schiller, Gary J.
    Wieduwilt, Matthew Joseph
    Oliai, Caspian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    Jaddaoui, Samiha
    Bencharef, Hanaa
    Addakiri, Sara
    Dehbi, Hind
    Lamchahab, Mouna
    Quessar, Asmaa
    Madani, Abdellah
    Oukkache, Bouchra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S256
  • [43] Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia
    Liu, Qingyang
    Yang, Jingjing
    Lv, Lei
    Zhang, Xiawei
    Li, Meng
    Xu, Lingmin
    Huang, Sai
    Jing, Yu
    Dou, Liping
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [44] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    Zeidan, Amer M.
    Westermann, Joerg
    Kovacsovics, Tibor
    Assouline, Sarit
    Schuh, Andre C.
    Kim, Hee-Je
    Macias, Gabriela Rodriguez
    Sanford, David
    Luskin, Marlise R.
    Stein, Eytan M.
    Malek, Kamel
    Lyu, Jiaying
    Stegert, Mario
    Esteve, Jordi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S255
  • [45] Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis
    Venditti, Adriano
    Hou, Jing-Zhou
    Fenaux, Pierre
    Jonas, Brian A.
    Vrhovac, Radovan
    Montesinos, Pau
    Garcia, Jacqueline S.
    Rizzieri, David
    Thirman, Michael J.
    Kotey, Stanley
    Potluri, Jalaja
    Dhalla, Mazaher
    Pullarkat, Vinod
    BLOOD, 2023, 142
  • [46] Venetoclax in Combination with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Is Comparable to Alternative Regimens
    Miller, Jenn
    Shannon, Lindsey
    Finch, Amanda
    Altman, Jessica K.
    Wojenski, Daniel
    BLOOD, 2020, 136
  • [47] RESULTS OF A PHASE 1B STUDY OF VENETOCLAX PLUS DECITABINE OR AZACITIDINE IN UNTREATED ACUTE MYELOID LEUKEMIA PATIENTS ≥65 YEARS INELIGIBLE FOR STANDARD INDUCTION THERAPY
    Pollyea, D. A.
    Di Nardo, C.
    Thirman, M.
    Letai, A.
    Wei, A.
    Jonas, B. A.
    Arellano, M.
    Frattini, M.
    Kantarjian, H.
    Chyla, B.
    Zhu, M.
    Potluri, J.
    Humerickhouse, R.
    Mabry, M.
    Konopleva, M.
    Pratz, K.
    HAEMATOLOGICA, 2016, 101 : 44 - 44
  • [48] A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia
    Lancet, Jeffrey E.
    Roboz, Gail J.
    Cripe, Larry D.
    Michelson, Glenn C.
    Fox, Judith A.
    Leavitt, Richard D.
    Chen, Tianling
    Hawtin, Rachael
    Craig, Adam R.
    Ravandi, Farhad
    Maris, Michael B.
    Stuart, Robert K.
    Karp, Judith E.
    HAEMATOLOGICA, 2015, 100 (02) : 231 - 237
  • [49] Phase 1 Dose Escalation Trial of Pegcrisantaspase in Combination with Venetoclax in Adults with Relapsed or Refractory Acute Myeloid Leukemia
    Bollino, Dominique R.
    Liu, Yuchen
    Bah, Osman Mohamed
    Caprinolo, Katherine
    Zarrabi, Jinoos
    Philip, Sunita
    Mostafa, Ezzat
    Lapidus, Rena G.
    Singh, Zeba
    Kallen, Michael
    Ning, Yi
    Koka, Rima
    Baer, Maria R.
    Niyongere, Sandrine
    Duong, Vu H.
    Strovel, Erin T.
    Graveno, Molly
    Emadi, Ashkan
    BLOOD, 2022, 140 : 9044 - 9045
  • [50] Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.
    Dohner, Hartmut
    Montesinos, Pau
    Polo, Susana Vives
    Zarzycka, Ewa
    Wang, Jianxiang
    Bertani, Giambattista
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    Burguera, Adolfo de la Fuente
    Cerchione, Claudio
    Daigle, Scott
    Hui, Jianan
    Pandya, Shuchi Sumant
    Gianolio, Diego A.
    Recher, Christian
    De Botton, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345